BPaLM Regimen Is the New Ray of Hope for Drug-Resistant TB
3 months, 2 weeks ago

BPaLM Regimen Is the New Ray of Hope for Drug-Resistant TB

Deccan Chronicle  

Hyderabad: Patients of drug-resistant tuberculosis in the state will soon get a new regimen, which is expected to bring down the cost and also the time of treatment from 20 months to six. BPaLM regimen, a novel treatment method for Multi-DrugResistant Tuberculosis includes a new anti-TB drug called pretomanid, which has earlier been approved and licenced for use in India by the Central Drugs Standard Control Organisation. We should not use a single drug in TB to avoid drug resistance," said Dr A. Rajesham, joint director, of TB cell. The new regimen is likely to attack Mycobacterium in a more effective manner, allowing a shorter recovery time.

Drug Bpalm Regimen Mdr Regimen  effective  treatment  regimen  drug  ray  drugresistant  pretomanid  drugs  hope  tuberculosis  usually  tb  resistance  bpalm

History of this topic

​Taking TB seriously: The Hindu Editorial on the BPaLM treatment regimen for drug-resistant tuberculosis
3 months, 2 weeks ago

​Taking TB seriously: The Hindu Editorial on the BPaLM treatment regimen for drug-resistant tuberculosis

The Hindu  

Time is of the essence in adopting advanced technology in medical care. The Union Health Ministry’s decision to introduce the new treatment regimen for drug-resistant tuberculosis hardly a couple of years after it was recommended by the World Health Organization, is a step in the right direction. This regimen has been proven to offer better outcomes, remarkably shortening the duration …

Health ministry approves shorter, more effective treatment for multi-drug-resistant TB
3 months, 2 weeks ago

Health ministry approves shorter, more effective treatment for multi-drug-resistant TB

Hindustan Times  

The Union health ministry has approved the shorter, less toxic, and more effective treatment regimen — BPaLM— against the multi-drug-resistant tuberculosis under its National TB Elimination Program. “While traditional MDR-TB treatments can last up to 20 months with severe side effects, BPaLM regimen can cure the drug-resistant TB in just six months with high treatment success rate,” the health ministry …

Health Ministry approves new treatment regimen for multidrug-resistant TB
3 months, 2 weeks ago

Health Ministry approves new treatment regimen for multidrug-resistant TB

The Hindu  

The Union Health Ministry has approved the introduction of a new treatment regimen for drug-resistant tuberculosis in India. The BPaLM regimen consisting of four drugs — Bedaquiline, Pretomanid, Linezolid and Moxifloxacin — has proven to be a safe, more effective and quicker treatment option than the previous Multidrug-Resistant Tuberculosis treatment procedure, the Ministry said on Friday. While traditional treatments can …

Solving the challenge of drug-resistant TB in India
4 months, 2 weeks ago

Solving the challenge of drug-resistant TB in India

Hindustan Times  

During the recent Maharashtra assembly session, questions were raised about the rising tuberculosis cases. The current treatment options available to us in India are limited; many come with severe side effects like severe peripheral neuropathy, pink to black brown discoloration of skin lasting up to three years, and potentially even psychosis, making it an extremely difficult, and at times hopeless …

Improved drug regimens for TB to cut treatment time
1 year ago

Improved drug regimens for TB to cut treatment time

The Hindu  

This November, at The Union World Conference on Lung Health 2023, there was much optimism, as it seemed that there were finally tools available to fast-track work on multiple aspects of TB control. Four, new improved drug regimens that could cut treatment time for drug resistant tuberculosis by up to two thirds, were the primary source of this optimism. According …

No shortage of anti-Tuberculosis drugs in India, asserts Health Ministry
1 year, 2 months ago

No shortage of anti-Tuberculosis drugs in India, asserts Health Ministry

The Hindu  

New Delhi The Union Health Ministry on September 25 said there is no shortage of anti-Tuberculosis drugs in India, asserting all these medicines are available with sufficient stocks ranging six months and above. It also termed as “vague and ill-informed” media reports alleging shortage of anti-TB drugs in India and questioning the effectiveness of such drugs under the National TB …

Significantly shorter treatment for drug-resistant TB likely soon
1 year, 9 months ago

Significantly shorter treatment for drug-resistant TB likely soon

Hindustan Times  

Mumbai: There’s some cheer in store for drug-resistant tuberculosis patients, who have been abiding a prolonged treatment regimen with severe side-effects. HT Image The present treatment guideline, which has 13 to 14 drugs given daily for a period of 18 to 24 months, was formulated two and a half years ago. The core committee of the National TB Elimination Programme …

Price reduction to aid in access of highly effective multidrug-resistant TB treatment
2 years ago

Price reduction to aid in access of highly effective multidrug-resistant TB treatment

Deccan Chronicle  

NEW DELHI: Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the price of Pretomanid, a drug used to treat multidrug-resistant tuberculosis, by 34%. “We welcome this news and commend Viatris, MedAccess, and TB Alliance for the announcement of a new agreement to reduce the price of pretomanid, a drug used to treat …

With over 90% Efficacy against Drug-resistant Disease, New TB Treatment Lets Experts Breathe Easy
2 years, 3 months ago

With over 90% Efficacy against Drug-resistant Disease, New TB Treatment Lets Experts Breathe Easy

News 18  

Discarding concerns of efficacy with a lower dose, a three-drugs-based new treatment regimen has a higher success rate than the existing drug-resistant TB treatment, says the latest ZeNix study published in the New England Journal of Medicine. The “bedaquiline-pretomanid-linezolid” regimen, abbreviated as the BPaL regimen, has been reported to have around 90% efficacy against highly drug-resistant tuberculosis, but the incidence …

Discover Related